Evidence map›Paper›PMID 29291159›Full record

ArticleNanotheranostics2018

Dual radiosensitization and anti-STAT3 anti-proliferative strategy based on delivery of gold nanoparticle - oligonucleotide nanoconstructs to head and neck cancer cells.

Surong Zhang, Suresh Gupta, Thomas J Fitzgerald, Alexei A Bogdanov

Open access · goldAbstract read
In one paragraph

Article in Nanotheranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Aptamer-based Advances in Skin Cancer Research.Current medicinal chemistry · 2023
    Review
  7. Review
  8. Review
  9. Multiplexed imaging in oncology.Nature biomedical engineering · 2022
    Review
  10. Review
  11. Article
  12. DNA Nanostructures and DNA-Functionalized Nanoparticles for Cancer Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020
    Review
  13. Review
  14. Gold Nanoparticles as Radiosensitizers in Cancer Radiotherapy.International journal of nanomedicine · 2020
    Review
  15. Review
  16. Non-invasiveTheranostics · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Surong ZhangLaboratory of Molecular Imaging Probes, Department of Radiology, University of Massachusetts Medical School, Worcester MA, USA.
Suresh GuptaLaboratory of Molecular Imaging Probes, Department of Radiology, University of Massachusetts Medical School, Worcester MA, USA.
Thomas J FitzgeraldDepartment of Radiation Oncology, University of Massachusetts Medical School, Worcester MA, USA.
Alexei A BogdanovLaboratory of Molecular Imaging Probes, Department of Radiology, University of Massachusetts Medical School, Worcester MA, USA.
University of Massachusetts Chan Medical School · US

Funding

MR SIGNAL AMPLIFICATION FOR RECEPTOR IMAGINGR01EB000858 · NIBIB · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BOGDANOV, ALEXEI A. · 2003 to 2022
$6.0M
Unruptured Intracranial Aneurysms: Rupture-Risk Assessment by Non-Invasive Molecular ImagingR01NS091552 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BOGDANOV, ALEXEI A., GOUNIS, MATTHEW JOHN · 2015 to 2018
$2.1M
Molecular fluorescence lifetime sensor of pro-inflammatory signaling in diabetesR01DK095728 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BOGDANOV, ALEXEI A. · 2014 to 2017
$1.5M
Engineering of multi-functional nucleolin-targeted nucleic acid delivery system.R21EB017980 · NIBIB · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ZHANG, SURONG · 2014 to 2015
$418k
NIBIB NIH HHS R01 EB000858NIBIB NIH HHS R21 EB017980NIDDK NIH HHS R01 DK095728NINDS NIH HHS R01 NS091552
6 · The paper itself

Abstract

Constitutively activated signal transducer and activator of transcription 3 (STAT3) factor is an important therapeutic target in head and neck cancer (HNC). Despite early promising results, a reliable systemic delivery system for STAT3- targeted oligonucleotide (ODN) drugs is still needed for future clinical translation of anti-STAT3 therapies. We engineered and tested a novel ODN duplex/gold nanoparticle (AuNP)-based system carrying a therapeutic STAT3 decoy (STAT3d) payload. This strategy is two-pronged because of the additive STAT3 antagonism and radiosensitizing properties of AuNP. The specificity to head and neck cancer cell surface was imparted by using a nucleolin aptamer (NUAP) that was linked to AuNP for taking the advantage of an aberrant presentation of a nuclear protein nucleolin on the cell surface. STAT3d and nucleolin aptamer constructs were independently linked to AuNPs via Au-S bonds. The synthesized AuNP constructs (AuNP-NUAP-STAT3d) exhibited internalization in cells that was quantified by using radiolabeled STAT3d. AuNP-NUAP-STAT3d showed radiosensitizing effect in human HNC FaDu cell culture experiments that resulted in an increase of cell DNA damage as determined by measuring γ-H2AX phosphorylation levels by flow cytometry. The radiosensitization study also demonstrated that AuNP-NUAP-STAT3d as well as STAT3d alone resulted in the efficient inhibition of A431 cell proliferation. While FaDu cells did not show instant proliferation inhibition after incubating with AuNP-NUAP-STAT3d, the cell DNA damage in these cells showed nearly a 50% increase in AuNP-NUAP-STAT3d group after treating with radiation. Compared with anti-EGFR humanized antibody (Cetuximab), AuNP-NUAP-STAT3d system had an overall stronger radiosensitization effect in both A431 and FaDu cells.

Indexed as

aptamerconfocal microscopygold nanoparticleoligonucleotideSTAT3.

Identifiers

PMID29291159
PMCPMC5743834
OpenAlexW2775632288

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.